DrugPatentWatch Database Preview

Details for Patent: RE39820

« Back to Dashboard

Which drugs does patent RE39820 protect, and when does it expire?

Patent RE39820 protects STIOLTO RESPIMAT, SPIRIVA, and SPIRIVA RESPIMAT, and is included in three NDAs.

Protection for SPIRIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in thirty-one countries.

Summary for Patent: RE39820

Title:	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Abstract:	Compounds of the formula ##STR00001## of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3.alpha.-(6.beta., 7.beta.-epoxy)-tropanyl methobromide and R.sub.1 is 2-thienyl; (b) A is 3.alpha.-(6, 7dehydro)-tropanyl methobromide and R.sub.1 is 2-thienyl; (c) A is 3.beta.-tropanyl methobromide and R.sub.1 is 2-thienyl; and, (d) A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide and R.sub.1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Inventor(s):	Banholzer; Rolf (Stuttgart, DE), Bauer; Rudolf (Ockenheim, DE), Reichl; Richard (Gau-Algesheim, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:	11/254,213
Patent Claim Types: see list of patent claims	Compound; Use; Composition; Dosage form;

Drugs Protected by US Patent RE39820

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes			Y	Y		TREATMENT OF COPD
Boehringer Ingelheim	SPIRIVA	tiotropium bromide	POWDER;INHALATION	021395-001	Jan 30, 2004		RX	Yes	Yes					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015		RX	Yes	No					Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: RE39820

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	39 31 041.8	Sep 16, 1989
	PCT/EP90/01517	Sep 08, 1990
	PCT/EP90/01517	Sep 8, 1990

Non-Orange Book US Patents Family Members for Patent RE39820

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
5,610,163	Esters of thienyl carboxylic acids and amino alcohols and their quaternization products

International Patents Family Members for US Patent RE39820

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Germany	3931041
Germany	10299026
Germany	59005250
Denmark	0418716